Loading...
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
AIM: To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet‐Biedl syndrome (BBS). MATERIALS AND METHODS: Individuals aged 12 years and older with BBS received once‐daily setmelanotide. The dose was tit...
Na minha lista:
| Udgivet i: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Blackwell Publishing Ltd
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7689750/ https://ncbi.nlm.nih.gov/pubmed/32627316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14133 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|